Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study

Other literature type, Article Spanish; Castilian OPEN
Marty, F. M.; Man, C. Y.; Van der Horst, C.; Francois, B.; Garot, D.; Mánez, R.; Thamlikitkul, V.; Lorente Balanza, José Ángel; Álvarez Lerma, F.; Brealey, D.; Zhao, H. H.; Weller, S.; Yates, P. J.; Peppercorn, A. F.; (2014)

Intravenous zanamivir is a neuraminidase inhibitor suitable for treatment of hospitalized patients with severe influenza. Patients were treated with intravenous zanamivir 600 mg twice daily, adjusted for renal impairment, for up to 10 days. Primary outcomes included adv... View more
Share - Bookmark